MIRA Pharmaceuticals (NASDAQ: MIRA) has announced positive results from preclinical studies evaluating optimized oral formulations of MIRA-55, the company’s oral drug candidate being developed as a non-opioid therapy for chronic inflammatory pain.
According to MIRA, following the evaluation of multiple oral formulations, the company selected a lead formulation demonstrating favorable oral bioavailability together with sustained systemic exposure and reproducible distribution into both brain and liver tissue following oral administration.
In a statement, Erez Aminov, CEO of MIRA, commented, “Patients deserve safer and more effective non-opioid treatment options for chronic inflammatory pain. These formulations and pharmacokinetic findings represent another important step in advancing MIRA-55 as a differentiated oral therapy designed to address that need.”
